Accelerating Small Molecule Drug Discovery
This article was originally published in Start Up
Executive Summary
Pharmaceutical companies face two giant risks; compound risk and target risk. So, despite an abundance of so-called validated targets emerging from genomics efforts, and novel high throughput tools for compound synthesis and screening that yield plenty of hits against each target, at the end of the day, pharmaceutical company productivity, as measured by approved drugs, remains low. Recently, several former big-pharma executives have founded private companies that hope to speed up the time it takes to come up with optimized small molecule leads. Each has staked out a particular niche where it thinks it can do better than big pharma at coming up with clinic-ready compounds. Kinetix Pharmaceuticals and Triad Pharmaceuticals hope to leverage their knowledge of particular gene families to come up with optimized leads; Enanta Pharmaceuticals hopes to morph peptides into drugs with a combinatorial approach to binding pharmacophores, and Sunesis hopes to tackle some of the targets that prove intractable for others, or in which only large molecules have been able to intervene. The new small molecule companies share a vision of drug discovery that is based on targets, rather than diseases.
You may also be interested in...
Theravance: Having Cake and Eating It
Thanks to productivity, lower-risk follow-on drugs and access to a Big Pharma balance sheet, Theravance is trying to demonstrate the possibility of getting paid for doing what biotech does best: research.
U3 Pharma AG
German start-up U3 Pharma AG is hoping that its focus on, and understanding of, full biological systems rather than simply on chemistry will give it a chance to win the race to find new cancer drugs.
Profits Are Not Enough: Vertex Buys Aurora
The low-risk model--don't develop drugs, develop technology and sell it to the drug industry--is on rapid rewind. The latest casualty: Aurora Biosciences, which has given up its lower-risk model of selling technology to throw its lot in with high-risk, high-value Vertex Pharmaceuticals. The moral of this story seems to be that it's better to find a seat at the table in a game with big stakes than simply get paid for dealing the cards.